Monitor the vote outcomes on the share increase and executive compensation, as these could signal management's capital allocation strategy and governance priorities. The recent board reshuffle suggests ongoing governance adjustments worth watching.
Price Chart
Executive Summary
Solid Biosciences is holding its 2026 annual meeting with several key proposals, including the ratification of Ilan Ganot's board appointment, a share increase to 480 million, and advisory votes on executive compensation. This follows a recent board reshuffle where Ganot was reappointed to a different class, indicating ongoing governance adjustments.
Key Facts
- Election of Class II directors Clare Kahn, Adam Stone, and Lynne Sullivan
- Ratification of Ilan Ganot's appointment to Class I director
- Ratification of PricewaterhouseCoopers as independent auditor
- Proposal to increase authorized shares from 240M to 480M
- Advisory vote on executive compensation
Financial Impact
Potential dilution from share increase from 240M to 480M authorized shares
Risk Factors
- Potential shareholder dilution if the share increase is approved and utilized
- Governance concerns if executive compensation receives significant opposition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-173684 |
| Document: 0001193125-26-173684-index-headers.html | 0001193125-26-173684 |
| Document: 0001193125-26-173684-index.html | 0001193125-26-173684 |
| Document: 0001193125-26-173684.txt | 0001193125-26-173684 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | S-3ASR | $8.39 $10.25 | ▲ +22.17% | ▲ +22.57% | $6.85 (−18.36%) |
May 12, 2026 20w ago | Press Release | $7.38 $7.22 | ▲ +2.17% | ▲ +1.56% | $6.85 (+7.18%) |
May 7, 2026 21w ago | Press Release | $7.07 $6.85 | ▼ −3.11% | ▼ −6.25% | $6.85 (−3.11%) |
Apr 23, 2026 23w ago | DEFA14A | $7.92 $6.50 | ▼ −17.93% | ▼ −21.96% | $6.85 (−13.51%) |
Apr 10, 2026 25w ago | 8-K | $8.39 $7.68 | ▼ −8.46% | ▼ −16.19% | $6.85 (−18.36%) |
Apr 1, 2026 26w ago | EFFECT | $7.38 $7.05 | ▲ +4.47% | ▲ +14.19% | $6.85 (+7.18%) |
Mar 19, 2026 28w ago | Press Release | $7.03 $8.49 | ▲ +20.77% | ▲ +11.45% | $6.85 (−2.56%) |
Mar 12, 2026 29w ago | 8-K | $7.71 $8.02 | ▲ +4.02% | ▲ +2.05% | $6.85 (−11.15%) |
Mar 11, 2026 29w ago | Press Release | $7.72 $8.10 | ▲ +4.99% | ▲ +4.47% | $6.85 (−11.21%) |
Mar 6, 2026 30w ago | Press Release | $6.75 $7.74 | ▲ +14.67% | ▲ +16.71% | $6.85 (+1.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access